美国食品药品监督管理局（FDA）已正式批准Sarepta Therapeutics公司提交其Essence临床研究数据及真实世界证据，作为支持新药申请（SNDAs）的关键材料。这一决定为Sarepta推进相关疗法审批流程扫清了重要障碍。
Essence研究旨在评估基因靶向疗法的安全性与有效性，而真实世界证据则能补充传统临床试验数据，提供更全面的疗效验证。FDA的认可标志着监管机构对创新证据采集方式的开放性态度，也为生物技术行业树立了新的审评标准。
此次突破将加速Sarepta在罕见病治疗领域的布局，同时为患者带来更早获得前沿疗法的可能。公司表示将按计划提交完整数据包，并与FDA保持密切沟通以推进后续流程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.